Matching articles for "Okedi"
Weltruza — A Once-Monthly Subcutaneous Formulation of Olanzapine
The Medical Letter on Drugs and Therapeutics • November 23, 2026; (Issue 1768)
Weltruza (Teva), a once-monthly subcutaneous (SC)
formulation of the second-generation antipsychotic drug
olanzapine, has been approved by the FDA for treatment of
schizophrenia in adults. A long-acting...
Weltruza (Teva), a once-monthly subcutaneous (SC)
formulation of the second-generation antipsychotic drug
olanzapine, has been approved by the FDA for treatment of
schizophrenia in adults. A long-acting intramuscular (IM)
formulation of olanzapine (Zyprexa Relprevv) is approved
for the same indication.
